Olaparib

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.^[1] See also Olaparib.

(4tvj).

See also:

• Mutations in BRCA1/BARD1 RING-domain heterodimer
• Mutations in Brca1 BRCT Domains